



## **Agenus to Present at Jefferies 2014 Global Healthcare Conference**

May 30, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced that Robert Stein, MD, PhD, the company's Chief Scientific Officer, is scheduled to present a company overview at the Jefferies 2014 Global Healthcare Conference in New York City on Thursday, June 5<sup>th</sup> at 1:00 pm ET.

### **Web Cast Information**

The live and archived webcast of the company presentation will be accessible from the company's website at [www.agenusbio.com/webcast](http://www.agenusbio.com/webcast). Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.

### **About Agenus**

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus' checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company's proprietary discovery engine Retrocyte Display<sup>®</sup> is used to generate fully human therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus' heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. The company's QS-21 Stimulon<sup>®</sup> adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. Among Agenus and its partners, 22 programs are in clinical development. For more information, please visit [www.agenusbio.com](http://www.agenusbio.com), or connect with the company on Facebook, LinkedIn, Twitter and Google+. For more information, please visit [www.agenusbio.com](http://www.agenusbio.com).

### **Forward-Looking Statement**

*This press release contains forward-looking statements, including statements regarding corporate presentations, research, development and clinical trial activities, and the potential application of the Company's technologies and product candidates in the prevention and treatment of diseases. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended March 31, 2014. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus' business and securities, investors should give careful consideration to these risks and uncertainties.*

### **Contact:**

Media and Investor Contact:  
Jonae R. Barnes, 617-818-2985  
Vice President  
Investor Relations and  
Corporate Communications  
[jonae.barnes@agenusbio.com](mailto:jonae.barnes@agenusbio.com)